• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Our people > Leadership > R&D
FabianaAlves2019

Dr Fabiana Alves

NTD Leishmaniasis-Mycetoma Cluster Director, DNDi

Fabiana Piovesan Alves joined DNDi in 2008, initially as a consultant on the Chagas disease and leishmaniasis projects. She is currently the NTD Leishmaniasis-Mycetoma Cluster Director.

Fabiana is a medical doctor, who graduated from the University of São Paulo, Brazil, with residency in Pediatrics. A PhD thesis on the molecular epidemiology of malaria in the Amazon region was followed by a post-doctoral position at TDR/WHO. She was a professor of parasitology at the University of São Paulo, coordinated projects at research institutes and also worked as a project manager for a clinical research organization.

Fabiana has 15 years of experience in research on tropical diseases, including malaria, leishmaniasis, Chagas disease and schistosomiasis, with the last 10 years principally in clinical research for the development of new treatments for neglected diseases, managing clinical trials from Phase I through to Phase III.

Featured news & publications

Loading...
  • A balancing act: Navigating the advantages and challenges of pioneering mycetoma treatment in Sudan – A landmark trial by the Mycetoma Research Center
  • Unsupervised machine learning identifies biomarkers of disease progression in post-kala-azar dermal leishmaniasis in Sudan
  • Patient insights research exploring disease awareness, patient life experience, and current management of visceral leishmaniasis in Bihar, India
  • Hope amidst neglect: Mycetoma Research Center, University of Khartoum. A holistic management approach to achieve the United Nations’ Sustainable Development Goals
  • Disease-specific differences in pharmacokinetics of paromomycin and miltefosine between post-kala-azar dermal leishmaniasis and visceral leishmaniasis patients in Eastern Africa
  • Differences in the cellular immune response during and after treatment of Sudanese patients with post-kala-azar dermal leishmaniasis, and possible implications for outcome
  • Design, conduct, analysis, and reporting of therapeutic efficacy studies in visceral leishmaniasis: A systematic review of published reports, 2000–2021
  • A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh
  • Climate change, malaria and neglected tropical diseases: a scoping review
  • Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia

Featured events

Loading...
  • Twelfth EDCTP Forum
  • ASTMH 2024
  • La enfermedad fúngica: una amenaza global oculta por olvidada
  • ECTMIH 2023
  • MSF Scientific Days – Asia 2023

Our global footprint

Loading...
Doctors talking with patient in hospital

DNDi DRC

Female healthcare worker taking care of a little girl

DNDi Eastern Africa

DNDi Japan

Female patient discussing with doctor

DNDi Latin America

Female doctor with a patient in a hospital

DNDi North America

Community worker talking with people in a rural village

DNDi South Asia

Malaysian doctor talking with a man in a hospital

DNDi South-East Asia

Two people speaking in an office

DNDi Switzerland

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License